rIsk factors for InfectIon In aaV patIents
The patients were classified into Group I (19 patients who died of infection) and Group II (22 who died of vasculitis). No difference was observed in age, sex, RPGN, or renal failure between the two groups. However, the incidences of lung bleeding, gastrointestinal bleeding, and disturbed consciousness were significantly lower in Group I than in Group II ( p <0.01). The percentage of patients treated with CS (prednisolone: PSL) <60 mg/day was significantly lower in Group I than in Group II ( p <0.05). These results suggest that continuation of the dose of prednisolone as CS ≥60 mg/day for AAV increases the risk of infection. Keller, et al. 5 ) also observed long-term courses in 155 patients with WG, and reported that CY administration is indispensable for the remission of WG and prevention of its recurrence, recommending that the PSL dose should be reduced to 5-10 mg/day within 3-5 months during the remission introduction stage. As Fig. 1 shows, there were 29 cases of infection as adverse events in 19 of 50 patients in the JMAAV registry (a prospective cohort study on Japanese patients with MPO-ANCA-associated vasculitis: chief researcher, Shoichi Ozaki; chairman, Shunichi Kumagai). Of 27 patients using CY, 14 (17 cases) developed infection. Although the time of the development of infection was evaluated, various infections developed from the The clinical signs and symptoms frequently observed were systemic symptoms such as fever and weight loss, and renal [rapidly progressive glomerulonephritis: RPGN], respiratory (lung bleeding, interstitial pneumonia), and upper respiratory tract [eyes, nose, ears] manifestations. In addition, arthralgia, myalgia, skin symptoms, and neuropsychiatric manifestations were observed. The laboratory findings included an increase in ANCA correlated with disease activity, an increase in CRP, proteinuria, hematuria, azotemia/hypercreatininemia, a positive rheumatoid factor, and hyper-g globumenia. The histological findings included granulomatous inflammation, capillaritis, and necrotizing angiitis. 1, 2) In the active stage of AAV before treatment, the ANCA titer and CRP level were high. After a decrease in the activity of vasculitis following the introduction of immunosuppressive therapy, both the ANCA titer and CRP level tended to decrease and become negative. 1, 2) The standard treatment method considered to be effective was combination therapy with high-dose CS and IS, mainly cyclophosphamide (CY). For RLV, plasma pheresis used in combination with the standard method was also effective for improving the outcome. Concerning the outcome of AAV, improvement/remission was observed in 60%-70% and aggravation in 10%-30%, and 41 patients died. The most frequent cause of death was infection (19 patients, 37%). The contents of infection included pneumonia and sepsis, and the most frequent causative microorganisms were fungi (such as aspergillus 4) ), followed in order by gram-positive bacteria (including MRSA), acid-fast bacteria, and cytomegalovirus. 3) including CS pulse therapy, the leukocyte (neutrophil) and platelet counts decreased to 1,200 (500)/mm 3 and 0.2 × 10 4 /mm 3 , respectively, and the patient died of respiratory failure due to pulmonary aspergillosis (confirmed by autopsy). At the time of the onset and aggravation of pulmonary aspergillosis, the anti-CSBG antibody titer acutely decreased from 1,400 to 700U. The measurement of the anti-CSBG antibody in patients with AAV is useful for evaluating the natural or acquired immune capacity of the host against b glucan and predicting the development of deep-seated mycosis as a complication, and this antibody titer can be a clinical parameter for optimal immunosuppressive therapy for AAV and anti-infection measures. 7, 8) As shown in Fig. 4 , AAV frequently develops in aged people, and induces systemic vasculitis causing disorders in the kidneys and respiratory organ as two major vital organs. As treatment, CS is administered, causing immunocompromised hosts. Fig. 3 shows a scheme of dysfunction of the immune system and the pathogen according to the type of IS. CS inhibits not only antigen processing by macrophages and antigen presentation by T cells but also interleukin 1 production and receptor expression, cellular/humoral immunity, and neutrophil function, exerting potent anti-inflammatory early to late period, and no consistent tendency was observed. The use of CY was a risk factor (3.877-fold risk) for developing infection. 6) 
Anti-b Glucan Antibody as a Marker Predicting Mycosis Including Pneumocystis Jirovecii Pneumonia (PCP) as a Complication in Patients with AAV
Recently, we established an antibody to b-glucan in the solubilized Candida cell wall as an antigen using ELISA. 7) The anti-CSBG antibody recognizes the straight chain b6 structure of b glucan, and its specific immune responses to b glucan were confirmed using an inhibition test. As shown in Fig. 2 , the anti-CSBG antibody titer was significantly lower in 14 patients with AAV in the active stage before treatment (691 ± 522 U) and 24 with AAV after immune suppression (547 ± 416 U) than in 22 healthy controls (671 ± 1,686 U). Evaluation of changes in the anti-CSBG antibody showed a gradual increase in the antibody titer in patients showing remission of vasculitis syndrome after immunosuppressive therapy. As shown in Fig. 3 , in the early stage of AVV in which MPO-ANCA was positive (68 U), and pulmonary and renal vasculitis (RPGN + dyspnea due to acute interstitial pneumonia) was observed, both the b glucan (>300 U) and aspergillus antigen levels were positive, and the anti-CSBG antibody titer was extremely low (100U). After 2 courses of CS pulse therapy for AAV, MPO-ANCA decreased, pulmonary and renal vasculitis improved, and the anti-CSBG titer also gradually increased to 800U. Two months after onset, during high-dose administration (≥37°C) persisting for 3 days or more and an increase in CRP are observed after remission of vasculitis in patients with AAV, infection as a complication is suspected. The severity of infection is evaluated based on the presence or absence of organ manifestations suggesting infection, leukocyte (neutrophil) count (<2,000 (600)/mm 3 ), lymphocyte count (CD4, 200/ml), and IgG (<600 mg/dl), and a search for and prevention of various possible microorganisms (bacteria, fungi, viruses, and protozoa) and treatment are thoroughly performed. In particular, administration of ST mixture (Baktarn ® ) 13, 14) as a treatment drug for carinii pneumonia (4-6 tablets/ day/week) is useful for preventing recurrence of AAV, mainly WG, and development of carinii pneumonia as a frequent infection in AAV while gargling with Fungizonen ® fluid (2,400 mg Fungizone ® /500 ml distilled water) and oral administration of itraconazole (ITCZ) (100-200 mg/day) are useful for preventing deep-seated fungal infection. Use of these methods in the early stage is recommended. 15) preVentIVe and treatment methods for pcp
Concerning the preventive and treatment methods for PCP, see the guidelines 16) proposed by the Research Group for Complications and their Treatment Methods and immunosuppressive effects. On the other hand, cyclosporine inhibits interleukin 2 production and receptor expression, inhibiting cellular immunity. Azathioprine (AZ) and CY are metabolic antagonists and have myelosuppressive effects on cellular and humoral immunity, sometimes causing neutropenia. 9) As shown in Fig. 3 , concerning the diagnostic criteria for immunodeficiency, 10) CD4 lymphocyte counts ≤200/ml indicate cellular immunodeficiency, IgG ≤600 mg/dl indicate humoral immunodeficiency, and neutrophil counts ≤600/ml indicate neutropenia. Treatment and control after the early identification of causative microorganisms using mycological, histological, and genetic tests for frequently occurring bacteria, viruses, and fungi are important. Concerning a draft for anti-infection measures in AAV (2002), we proposed the flow chart shown in Fig. 5 11, 12) after discussion and detailed evaluation by 9 members of the Subcommittee on Treatment (Chairman, Masaharu Yoshida) of the Research Committee on Intractable Vasculitis (Chairman before the former chairman, Hiroshi Hashimoto), Ministry of Health, Labour and Welfare. AAV activity is comprehensively evaluated based on the ANCA titer, increases in the CRP and LDH levels, and characteristic signs and symptoms of vasculitis, mainly those in the lungs and kidneys. 1) For AAV, optimal immunosuppressive therapy is performed with a consideration of the disease type and severity. When fever 
